KR100937205B1 - 개선된 특성을 갖는 혼성물질 및 그 제조 방법 - Google Patents
개선된 특성을 갖는 혼성물질 및 그 제조 방법 Download PDFInfo
- Publication number
- KR100937205B1 KR100937205B1 KR1020070073442A KR20070073442A KR100937205B1 KR 100937205 B1 KR100937205 B1 KR 100937205B1 KR 1020070073442 A KR1020070073442 A KR 1020070073442A KR 20070073442 A KR20070073442 A KR 20070073442A KR 100937205 B1 KR100937205 B1 KR 100937205B1
- Authority
- KR
- South Korea
- Prior art keywords
- active ingredient
- micelle
- hybrid material
- biocompatible
- inorganic structure
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
Claims (15)
- 활성성분이, 생체 친화성 공중합 고분자 계면활성제 EOnPOmEOn (n은 20 내지 106의 정수이며, m은 40 내지 100의 정수이다)의 미셀 중에 담지된 활성성분-미셀의 복합체가 이산화규소 또는 이산화티타늄으로 이루어진 메조 다공성 무기 구조체의 동공 중에 혼성화된 혼성물질.
- 삭제
- 삭제
- 제 1 항에 있어서, 상기 메조 다공성 무기 구조체는 구형인 것을 특징으로 하는 혼성물질.
- 제 1 항에 있어서, 상기 메조 다공성 무기 구조체의 직경은 1 내지 10 ㎛인 것을 특징으로 하는 혼성물질.
- 제 1 항에 있어서, 상기 메조 다공성 무기 구조체의 동공의 크기는 2 내지 10 nm인 것을 특징으로 하는 혼성물질.
- 제 1 항에 있어서, 상기 활성성분은 수난용성 약물인 것을 특징으로 하는 혼성물질.
- 제 6 항에 있어서, 상기 수난용성 약물은 C2-세라마이드, 레티놀, 토코페롤, 및 베타카로틴으로 구성된 그룹에서 선택되는 것을 특징으로 하는 혼성물질.
- 활성성분, 임계 미셀형성농도 이상의 생체 친화성 공중합 고분자 계면활성제 EOnPOmEOn (n은 20 내지 106의 정수이며, m은 40 내지 100의 정수이다), 및 무기 전구체의 혼합 수용액을 25 내지 40℃에서 반응시켜 생체 친화성 공중합 고분자 계면활성제의 미셀 중에 활성성분이 담지된 활성성분-미셀의 복합체를 형성하는 단계; 및상기 활성성분-미셀의 복합체가 형성된 수용액을 80 내지 130℃에서 수열 반응시켜 유기-무기 복합체를 제조하는 단계를 포함하는, 제 1 항 및 제 4 항 내지 제 7 항 중 어느 한 항에 따른 혼성물질의 제조방법.
- 제 9 항에 있어서, 상기 활성성분-미셀의 복합체를 형성하는 단계에서 산을 부가하여 무기 전구체의 표면 전하를 중성으로 하는 단계를 추가로 더 포함하는 것을 특징으로 하는 제조방법.
- 제 10 항에 있어서, 상기 산은 염산, 황산, 또는 인산인 것을 특징으로 하는 제조방법.
- 제 9 항에 있어서, 상기 무기 전구체는 테트라에틸 오르토실리케이트(TEOS), 테트라메틸 오르토실리케이트(TMOS), 이산화규소, 및 소듐 실리케이트로 구성된 그룹에서 선택되는 것을 특징으로 하는 제조방법.
- 제 9 항에 있어서, 상기 혼합 수용액 중의 활성성분의 농도는 생체 친화성 공중합 고분자 계면활성제에 대해 100 중량% 이하인 것을 특징으로 하는 방법.
- 제 9 항에 있어서, 상기 혼합액 중의 무기전구체의 생체 친화성 고분자 계면활성제에 대한 몰비는 1:0.0035 ~ 1:0.005의 범위인 것을 특징으로 하는 방법.
- 제 1 항, 및 제 4 항 내지 제 8 항 중 어느 한 항에 따른 혼성물질을 포함하는 완제품.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20060069185 | 2006-07-24 | ||
KR1020060069185 | 2006-07-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080009653A KR20080009653A (ko) | 2008-01-29 |
KR100937205B1 true KR100937205B1 (ko) | 2010-01-19 |
Family
ID=39221995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070073442A KR100937205B1 (ko) | 2006-07-24 | 2007-07-23 | 개선된 특성을 갖는 혼성물질 및 그 제조 방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100937205B1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101138237B1 (ko) * | 2010-04-12 | 2012-04-24 | (주)일천 | 미용소금 복합체, 이를 제조하는 방법 및 이를 포함하는 미용용품 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US6303290B1 (en) | 2000-09-13 | 2001-10-16 | The Trustees Of The University Of Pennsylvania | Encapsulation of biomaterials in porous glass-like matrices prepared via an aqueous colloidal sol-gel process |
KR20060024637A (ko) * | 2004-09-14 | 2006-03-17 | (주)선한엠엔티 | 메조 크기 동공을 갖는 다공성 이산화티탄 박막용 중성콜로이드 용액 및 그 제조방법 |
KR20070068871A (ko) * | 2005-12-27 | 2007-07-02 | 재단법인서울대학교산학협력재단 | 무기계 나노입자가 내포된 메조 세공 실리카 나노입자 및그 제조 방법 |
-
2007
- 2007-07-23 KR KR1020070073442A patent/KR100937205B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US6303290B1 (en) | 2000-09-13 | 2001-10-16 | The Trustees Of The University Of Pennsylvania | Encapsulation of biomaterials in porous glass-like matrices prepared via an aqueous colloidal sol-gel process |
KR20060024637A (ko) * | 2004-09-14 | 2006-03-17 | (주)선한엠엔티 | 메조 크기 동공을 갖는 다공성 이산화티탄 박막용 중성콜로이드 용액 및 그 제조방법 |
KR20070068871A (ko) * | 2005-12-27 | 2007-07-02 | 재단법인서울대학교산학협력재단 | 무기계 나노입자가 내포된 메조 세공 실리카 나노입자 및그 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20080009653A (ko) | 2008-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maleki et al. | Synthesis and biomedical applications of aerogels: Possibilities and challenges | |
Saha et al. | Soft-templated mesoporous carbons as potential materials for oral drug delivery | |
Jesus et al. | Highly controlled diffusion drug release from ureasil–poly (ethylene oxide)–Na+–montmorillonite hybrid hydrogel nanocomposites | |
Li et al. | Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity | |
US20090252811A1 (en) | Capped mesoporous silicates | |
Rehman et al. | The applicability of ordered mesoporous SBA-15 and its hydrophobic glutaraldehyde-bridge derivative to improve ibuprofen-loading in releasing system | |
WO2016030913A2 (en) | Chemically stable hollow spherical cof and synthesis thereof | |
US20100104650A1 (en) | Charged mesoporous silica nanoparticle-based drug delivery system for controlled release and enhanced bioavailability | |
US20050130827A1 (en) | Decomposable monotithic ceramic materials having an at least bimodal pore distribution and active metal centers located in the pores | |
González et al. | A novel synthetic strategy for covalently bonding dendrimers to ordered mesoporous silica: potential drug delivery applications | |
Cheng et al. | YVO 4: Eu 3+ functionalized porous silica submicrospheres as delivery carriers of doxorubicin | |
CN103534208B (zh) | 无机粒子材料的制造方法 | |
EP2894186A1 (en) | Disintegrable porous organometaloxide material | |
US20130177934A1 (en) | Aminated Mesoporous Silica Nanoparticles, Methods of Making Same, and Uses Thereof | |
KR100831348B1 (ko) | 3차원 기공구조를 가지는 나노다공성 생체활성 유리 및 이의 합성 방법 | |
Ganesh et al. | Development of duloxetine hydrochloride loaded mesoporous silica nanoparticles: characterizations and in vitro evaluation | |
Czarnobaj | Sol–gel-processed silica/polydimethylsiloxane/calcium xerogels as polymeric matrices for Metronidazole delivery system | |
Ayad et al. | pH-responsive sulphonated mesoporous silica: a comparative drug release study | |
Saroj et al. | Etoposide encapsulated functionalized mesoporous silica nanoparticles: Synthesis, characterization and effect of functionalization on dissolution kinetics in simulated and biorelevant media | |
Airoldi et al. | Hydrophobic contribution to amoxicillin release associated with organofunctionalized mesoporous SBA-16 carriers | |
CN105764852A (zh) | 用于生产无机颗粒材料的方法 | |
KR100937205B1 (ko) | 개선된 특성을 갖는 혼성물질 및 그 제조 방법 | |
Hodali et al. | Evaluation of mesoporous silicate nanoparticles for the sustained release of the anticancer drugs: 5-fluorouracil and 7-hydroxycoumarin | |
Li | Mesoporous bioactive glass functionalized with AIEgens for pH sensing and drug delivery | |
Duan et al. | Characterization and performance evaluation of pH-sensitive drug delivery of mesoporous silica with honeycomb structure for treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
E801 | Decision on dismissal of amendment | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090121 Effective date: 20091224 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130109 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140109 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150707 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151231 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170106 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180104 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200107 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20200109 Year of fee payment: 12 |